Medicines are becoming a major component of health expenditure in China. Selection of effective and cost-effective medicines represents an important effort to improve medicines use. A guideline on cost-effectiveness studies has been available in China. This guideline, however, fails to be a practical tool to prepare and critically appraise economic evidence. This article discusses, in the Chinese context, the approach to integrating economic component into the medicines selection, and elaborates the methods of producing economic evidence, including conducing economic reviews and primary economic studies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1756-5391.2010.01087.x | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!